Tempest Therapeutics logo
Tempest Therapeutics
TPST | NASDAQ
Chart Builder DCF Calculator
$0.50
-$0.03 (-6.23%)
At close: Oct 30, 2026, 4:00 PM ET

Tempest Therapeutics Company Profile

Company profile explained

Company Profile

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

Key Executives

Name Position
Matthew Angel Chief Executive Officer, President & Director
Andrew Fang Head of Business Development
Justin Trojanowski VP of Finance, Corp. Controller, Treasurer, Secretary and Principal Financial & Accounting Officer
Nicholas J. Rossettos CFO, Principal Financial & Accounting Officer, Treasurer and Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 3 Filing
Oct 02, 2026 424B3 Filing
Oct 01, 2026 EFFECT Filing
Sep 28, 2026 8-K Current Report
Sep 25, 2026 S-3 Filing
Sep 17, 2026 8-K Current Report
Sep 16, 2026 DEFA14A Filing
Sep 16, 2026 8-K Current Report
Sep 15, 2026 8-K Current Report
View All SEC Filings ➞
Tempest Therapeutics
Tempest Therapeutics logo
Country United States
IPO Date Nov 12, 2012
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Matthew Angel

Contact Details

2000 Sierra Point Parkway Brisbane, California 94005 United States

Stock Details

Ticker Symbol TPST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001544227
CUSIP Number 87978U207
ISIN Number US87978U2078
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.